Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
|Articles|January 2, 2009
The Co-Pay Connection - Dr. A. Mark Fendrick of the University of Michigan
Author(s)A. Mark Fendrick, MD
Dr. A. Mark Fendrick explains the concept of Value-Based Insurance Design (VBID) and how it works.
Advertisement
Our Co-Editor-in-Chief, Dr. A. Mark Fendrick, explains the concept of Value-Based Insurance Design (VBID) and discusses the implications of reducing co-pays for employers and insurers.
Advertisement
Related to this article
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
2
Surrogate End Points, Drug Costs Complicate Oncology Formularies
3
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
4
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
5